Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

Azerion Stock Collapses 93% In 10 Sessions: What Is Happening?

Loading stream...
(VIANEWS) - Shares of Azerion Warrants (AEX-Index: AZRNW.AS) plunged an extraordinary 93.33% within 10 sessions - from EUR0.15 to EUR0.01, to 15:08 EST on Monday - as this dramatic decline followed five consecutive sessions of losses and two losses on the AEX-Index; Azerion Warrants' last close was EUR0.01, equalling its 52-week high at that level.

Yearly Analysis

According to available information, AZERION WARRANTS's stock is trading at EUR0.01, significantly higher than its 52-week high of EUR0.01 this year. This may suggest that its peak may already have passed and signal short term consolidation or correction is imminent; however, investors must remember that past performance cannot guarantee future returns and conduct further analysis and research before making investment decisions. More news about AZERION WARRANTS (AZRNW.AS).

Categories

stockMarket

Tags

Stock PriceAZRNW.ASAZERION WARRANTSPrice DownMarket Session NowStock Price DownStock Market NowMarket SessionStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com